Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...

Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

Actor Mel Gibson recently opened up about a challenging chapter in his life, sharing details of his battle with COVID-19 and ...

The 69-year-old actor opened up about his harrowing experience which took place during the pandemic on Joe Rogan's podcast.

ORG Partners LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 0.3% in the 4th quarter, ...

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

Poolbeg Pharma updated the market on its potential combination with Hookipa Pharma on Friday, clarifying Gilead Sciences’ ...

These nuggets of wisdom provide a snapshot of the actionable insights needed to help fleets become more sustainable, efficient, productive, and safe.

Seasoned advisory group including RNA, translation and commercialisation luminaries.

Royalty Pharma will present at the 43rd Annual J.P. Morgan Healthcare Conference at 6:45 p.m. ET / 3:45 p.m. PT on January 14, 2025. The webcast will be accessible from Royalty Pharma's "Events” page ...

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

Daily roundup of research and analysis from The Globe and Mail’s market strategist Scott Barlow ...